Global Market Access

Strategic Global Market Excellence

Craft a Winning Global Market Access Strategy

Navigating pharmaceutical market access is a complex journey, involving competitive pressures, regulatory hurdles, and varied pricing and reimbursement structures. Success requires proving drug efficacy, securing favorable reimbursement, and managing Health Technology Assessments (HTAs).

At The Dedham Group, we simplify this process with expert knowledge and tailored, holistic services. Our deep understanding of diverse markets ensures a seamless journey to global market entry.

Schedule a Meeting

Our Tailored Services for Success:

Learn more about the Dedham Group’s Expertise in Global Market Access:

Expert Guidance

Our seasoned team of access and value influencers stays ahead of the curve, providing real-time insights into emerging access challenges and value drivers.

Global Reach

Whether it’s the UK, the US, China, or any major healthcare market, we have the expertise to navigate diverse pricing and reimbursement structures.

Lifecycle Support

From drug development and launch to continuous monitoring, we stand by you throughout the entire lifecycle of your medical product.

Data-Driven Insights

Our panel delivers local-level data-driven insights, empowering you to make informed decisions and prioritize engagements effectively.

Related Case Studies:

Global Commercialization Strategy to Activate Outpatient Use

Global CoE sensitivities towards CAR-T utilization are assessed to archetype sites by outpatient commercialization approach and recommend engagement strategies based on market challenges.

Oncology Landscape and TPP Opportunity Testing

Global pricing and market access assessment of different TPP scenarios with detailed outcomes by each endpoint, expected HTA score, and utilization to optimize clinical trial design.

Operational Workflows and Site Activation

Global assessment of expected workflows and capacity influences to model CoE and country capacity and prioritized the number of CoEs to be certified per market to meet demand.

Additional Resource

Why U.S. Market Access Strategies Do Not Translate in Ex-U.S. Markets

As the U.S. is the largest pharmaceutical market by revenue, many pharmaceutical manufacturers have dedicated U.S.-specific departments and teams to support new therapy launches. Manufacturers may typically group all non-U.S. markets into “global” or “ex-U.S.” strategies, simplifying the global pharmaceutical market space into two archetypes.